Friday, July 10, 2026
🇺🇸 FDA

pharma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · metastatic or unresectable, recurrent HNSCC

Createrna Science and

Wuhan Createrna Science and Technology Co., Ltd

Createrna Science and clinical programs — 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
shanghai, CN, London HQ
26 Employees
NMPA registrant Type
Company details
Status
Public
HQ
shanghai, CN, London
Employees
26
Programs
51
Drugs
87
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Createrna Science and projects

51 ClinicalTrials.gov programs sponsored by Createrna Science and.

Createrna Science and has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

51 programs

Clinical programs

Page 1 of 2

  1. AC-203-EBS-007

    Wuhan Createrna Science and Technology Co., Ltd

    Generalized Epidermolysis Bullosa Simplex (EBS)

    phase 3 small molecule active

    1 trial

  2. ALKS 4230-007

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  3. AT148006

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  4. BASICstudy

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic cluster headache

    phase 3 small molecule active

    1 trial

  5. HOVON 127 BL

    Wuhan Createrna Science and Technology Co., Ltd

    Burkitt lymphoma

    phase 3 small molecule active

    1 trial

  6. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Wuhan Createrna Science and Technology Co., Ltd

    Small-cell lung cancer, extensive stage

    phase 3 small molecule active

    1 trial

  7. LOXO-BTK-20019

    Wuhan Createrna Science and Technology Co., Ltd

    Mantle cell lymphoma

    phase 3 small molecule active

    1 trial

  8. LOXO-BTK-20020

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  9. LOXO-BTK-20022

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  10. LOXO-BTK-20023

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  11. LOXO-BTK-20030

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  12. LY06006/MRCT-301

    Wuhan Createrna Science and Technology Co., Ltd

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  13. TRIO041

    Wuhan Createrna Science and Technology Co., Ltd

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  14. 177Lu PSMA I&T solution for injection

    Wuhan Createrna Science and Technology Co., Ltd

    Recurrent grade 3 and grade 4 glioma

    phase 2 small molecule active

    1 trial

  15. 54767414LEU2002

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  16. ALKS4230-006

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced cutaneous melanoma and Advanced mucosal melanoma

    phase 2 small molecule active

    1 trial

  17. AT148003

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  18. AT148004

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  19. BSMO 1-2018

    Wuhan Createrna Science and Technology Co., Ltd

    Basket tumors

    phase 2 small molecule active

    1 trial

  20. DT-DEC01

    Wuhan Createrna Science and Technology Co., Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  21. Diamyd

    Wuhan Createrna Science and Technology Co., Ltd

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  22. EAE 115

    Wuhan Createrna Science and Technology Co., Ltd

    Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"

    phase 2 small molecule active

    1 trial

  23. EAE-2020/MM0107

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  24. EAE116

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial

  25. EAE120

    Wuhan Createrna Science and Technology Co., Ltd

    newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  26. EAE127

    Wuhan Createrna Science and Technology Co., Ltd

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  27. EAE128

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma

    phase 2 small molecule active

    1 trial

  28. EAE140

    Wuhan Createrna Science and Technology Co., Ltd

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  29. Etrinabdione oral solution

    Wuhan Createrna Science and Technology Co., Ltd

    Peripheral Arterial Disease

    phase 2 small molecule active

    1 trial

  30. ExPlas

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  31. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  32. HO155

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukemia, Myelodysplastic syndrome

    phase 2 small molecule active

    1 trial

  33. HO159

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

  34. LOXO-BTK-18001 BRUIN

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  35. LOXO-RET-18036

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  36. Mecasermin rinfabate

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lung Disease

    phase 2 small molecule active

    1 trial

  37. Piqray 50 mg and 200 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    metasatic breast cancer, hormon positive, her 2 negative

    phase 2 small molecule active

    1 trial

  38. SCO101-001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  39. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  40. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  41. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial

  42. Xospata 40 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukaemia, Acute myeloid leukaemia

    phase 2 small molecule active

    1 trial

  43. Zanubrutinib

    Wuhan Createrna Science and Technology Co., Ltd

    Cold agglutinin disease

    phase 2 small molecule active

    1 trial

  44. A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  45. A Study to evaluate the effect of a high-fat... for Healthy volunteer

    Wuhan Createrna Science and Technology Co., Ltd

    Healthy volunteer

    phase 1 other active

    1 trial

  46. DF-006-1001

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  47. BTIIMD-02-EC-23-OJOS

    Wuhan Createrna Science and Technology Co., Ltd

    Dry Eye Disease

    approved small molecule active

    1 trial

  48. BTIIMD-02-EC-23-OJOS

    Wuhan Createrna Science and Technology Co., Ltd

    Dry Eye Disease

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Createrna Science and have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.